Amgen, Inc. vs Prologis Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Prologis Inc trades at $139.07 (market cap $132.57B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Prologis Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| AMGN | PLD | |
|---|---|---|
Market Cap | $224.14B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $417.20 | $149.96 |
52-Week Low | $271.18 | $104.81 |
Enterprise Value | $267.45B | $167.31B |
Dividend Yield | 2.43% | 3.07% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →